BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS

View Clinical Trials from BioPharm Insight




Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


 Key Statistics


Email:
Ownership:

Web Site: Regeneron Pharmaceuticals, Inc.
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





 Company News
Regeneron Pharmaceuticals, Inc. (REGN) R&D Chief Reveals Allergy Drug May Be Darling Of Its Pipeline 9/19/2014 3:48:18 PM
Kymab Succeeds In Revoking Regeneron Pharmaceuticals, Inc. (REGN)’s European Patent 9/19/2014 10:14:54 AM
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA 9/16/2014 5:40:19 AM
Regeneron Pharmaceuticals, Inc. (REGN) Executive Outlines Strategy For Avoiding Affordable Care Act Penalties 9/15/2014 6:20:37 AM
Regeneron Pharmaceuticals, Inc. (REGN) Announces Submission Of Application For EYLEA® (Aflibercept) Injection In Japan For Macular Edema Following Branch Retinal Vein Occlusion 9/4/2014 11:22:48 AM
Early Phase 3 Data Suggest Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/2/2014 6:27:22 AM
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014 8:04:35 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Ring The NASDAQ Stock Market Opening Bell 8/20/2014 7:32:11 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Ring The NASDAQ Stock Market Opening Bell 8/19/2014 10:34:59 AM
Regeneron Pharmaceuticals, Inc. (REGN) Announces Upcoming 2014 Investor Conference Presentations 8/19/2014 8:23:10 AM
12345678910...